Cancer made casualty star Shalisha James-Davis make the most of life
Three years on, the harrowing experience has left Shalisha determined to make the most of every facet of life.The irony of playing a doctor in a fake hospital was not lost on her when she was wheeled into the real theatre space for emergency surgery in 2022."I didn't know what I was meant to feel," she said. "Grateful? Relieved? There was no toolbox, I had no-one to talk to about how I was meant to feel – so I just felt angry."Angry with myself for maybe not pushing more – angry with the NHS for taking one look at me and dismissing me because of my age, my demographic."The actor's symptoms had developed over a number of months in 2021, and when she returned from three months filming in Spain she spoke to her GP about back pain and bloating. She was referred for a scan, which revealed a four inch (10cm) tumour on her right ovary.After further investigations, she said a multi-disciplinary team at the hospital in Nottingham talked her through the results."They said because of my age, and the sort of cells that were inside my tumour, times that by X, multiply this by Y and Z - you don't have cancer," she said.
Shalisha was told there was a six-month wait for surgery to remove the tumour.She returned to the set of Casualty, relieved not to have cancer, but still with a distended stomach and "excruciating pain"."Bless the costume department - I couldn't really tell anyone, so I asked if they could just make my scrubs a bit bigger, because I couldn't have people thinking I was pregnant," she said. Not even Shalisha's family knew cancer was a possibility, as she did not want to scare them without knowing the full facts."It was a very lonely experience because it was just me and my husband going through this," she said.
Things came to a head in the spring of 2022."One morning in early March I woke the whole house up screaming - my tumour was twisting inside my abdomen," Shalisha said. "I couldn't keep painkillers down so we had to call an ambulance."Following surgery, doctors discovered the 12 inch by 12 inch (30cm x 30cm) tumour was mucinous ovarian cancer.
"I didn't let anyone apart from my husband and my best friend come and visit me in hospital, because I didn't want to see in my mum's eyes how sick I looked," Shalisha said. She said processing her diagnosis also came with challenges, adding: "The pamphlets and websites never showed anyone younger than 40, let alone a black woman."She credits the nurses volunteering with charity Black Women Rising with saving her life."There were times where I was at a point that if I didn't speak to someone right then, I was going to lose my mind and spiral – and I didn't know how to climb out of that," Shalisha said. "But even within that community, I still haven't met a young woman with mucinous ovarian cancer who is of my Caribbean heritage."There's a lot of culture there – a rich history that is instilled into me – of having my own back and being strong, and I needed another woman to be like 'girl, I get it, I understand'."
Shalisha also praised the after-care she received from the oncology team in Cardiff, but said her cancer had changed "every single facet of life" including her attitude to her own body.When she awoke from surgery she had around 29 staples down her stomach."It took me a long time to look in the mirror, and a while before I started to see how incredible it is and what it represents," she said. "Every time I get changed I'm reminded of what my body went through – but three years on I'm so proud of this tiny body that has got me to where I am now."Since leaving Casualty in 2024 Shalisha has taken on a number of theatre roles, presented Saying Yes to Life for BBC Radio wales, and also worked with charities to raise awareness of ovarian cancer, even though talking about it can still be difficult."People assume because I'm an actor I'm good at talking - but in work people write lines for me," she added."Speaking about my experience is completely new to me."
"Mucinous ovarian cancer is a rare form of cancer and the complexities of a case can make it challenging to diagnose," said Nottingham University Hospitals NHS Trust's director of nursing and professions Rachel Boardman."However, where there are concerns, various tests and scans are used to identify the cancer, which would be assessed at a multidisciplinary level, in order to maintain an accurate diagnosis and a treatment plan to be delivered as quickly as possible."Ask Eve nurse Helen Hyndman said: "I speak to many young women who get in touch with Ask Eve for advice who struggled to get their diagnosis of one of the five gynaecological cancers."Women tell me that they felt that because of their age, they were seen as 'too young' for cancer to be investigated."
What are the symptoms of gynae cancers?
There are five gynaecological cancers - womb, ovarian, cervical, vulval and vaginal.Ms Hyndman said: "The symptoms of the five cancers include abnormal vaginal bleeding, unexplained pelvic pain, changes to bladder or bowel habits or vulva itching, all of which can be caused by other much more common and less serious conditions. "This means it's usually appropriate to test for other conditions before checking for cancer in younger women and people with gynae organs. "But if you can't find a cause, or your symptoms persist or worsen, don't be afraid to mention the word cancer to your doctor and ask for tests."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
19 minutes ago
- BBC News
Lung cancer screening programme rolled out in Norfolk and Suffolk
A pilot lung cancer screening programme, which the NHS said had helped save lives, was being rolled out to more scheme was first launched for smokers and ex-smokers aged between 55 and 74 in Great Yarmouth, Norfolk, in 2022, before being extended to Lowestoft, Suffolk. It will now be available across the whole of Norfolk and people screened out of 8,000 were diagnosed with lung cancer, with 70% discovered at an early and more treatable stage, according to the NHS Norfolk and Waveney Integrated Care Board (ICB)."We've already seen a fantastic response... and that's why we're pushing ahead to offer more people the check," said Dr Suzanne Phillips from the board. "We're rolling this out in stages to tens of thousands of people, so it's really important people wait to be contacted about their check and book it in when offered."Lung cancer usually doesn't have many symptoms in its early stages, so that's why it's important we proactively check people who might be at risk of developing it."As part of the project, assessments with a medic are carried out initially, and lung scans are then offered if could attend a launch event between 10:00 BST and 13:00 on Tuesday, 26 August at the TIC mobile unit in Sainsbury's car park on the Hardwick industrial estate in King's Lynn, where free health checks will be offered. Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
BBC News
20 minutes ago
- BBC News
Bristol NHS merger could create major health organisation
A potential merger between Bristol's hospital trusts could create one of the biggest healthcare organisations in the UK, says its chief Kane, head of both North Bristol NHS Trust and the University Hospitals Bristol and Weston (UHBW) NHS Foundation Trust, says operating as a single organisation will result in "better outcomes" for the 1.5million patients the two trusts merger would reduce the duplication of services and possibly lead to an expansion of services at Southmead Kane said: "I have seen huge appetite from our clinicians to want to come together around what's best for patients." The North Bristol NHS Trust runs sites including Southmead Hospital, while UHBW runs the Bristol Royal Infirmary (BRI), St Michael's, Bristol Children's Hospital, Weston General Hospital and potential partnership between the two trusts would strengthen collaboration across Bristol, North Somerset and South Kane explained she has discovered a wide variation in outcomes for some of the 44 services that are duplicated on both sites, including cardiac care."One of our clinicians talked about the unfairness of getting in an ambulance and being very worried about whether it would turn left or right, because they knew the outcome could be very different," she added. Ms Kane said she hoped the possible merger will create one of the biggest hospital trusts in the UK, second to Manchester which employs more than 28,000 health professionals, and may result in an expansion of services in Southmead."We are setting up a community participation group because whatever we do has to align to need and be acceptable to local people, which we have to do with a finite budget," she Kane said the trusts would be assessing how demand for inpatient services should dictate how different buildings are used, but said she acknowledged people would still like to access services in the city centre. Different waiting lists The trusts are already working closely in specialties including cardiac services - where waiting lists for some minimally-invasive heart procedures are nine months at Southmead, compared with just six weeks at the trusts are using a private company to send mini stick-on heart monitors to patients at home, which they can post back to get a result within just two weeks. University of Bristol student Katherine Barnes has benefitted from the closer working relationship between both hospital trusts. She was diagnosed with an irregular heartbeat earlier this year, and is one of the patients who has used a patch monitor. The 21-year-old competitive cyclist said: "I had been having arrhythmias off and on for about 10 years, but it came on really suddenly during one of the biggest races of the season and so I had to pull out. "I received the patch in a recent appointment and I just sent it back to them and they analysed the data for me." The merger is also improving collaborations in research, including a potential cure for the rare kidney disease, IgA of paediatric nephrology at the University Hospitals Bristol, Moin Saleem, is teaming up with clinicians from Southmead to start a world-first study using gene therapy, which uses a virus to introduce genetic material into the IgA cell to cure them of the disease."The significance we hope will be pretty huge because at the moment there is no curative therapy for this disease," said Prof Saleem."If this switches off the disease then those patients will be able to avoid dialyses completely."Richard Betteridge has IgA nephropathy and hopes to go on the trial. The 32-year-old said: "It really does give you that sense of hope that there's something you can do, and you are also contributing to advancing the science around the management of this condition." Following the Government's 10-year plan, announced in July, a network of local health hubs will be created and Ms Kane added this move will allow them to transfer services to community health hubs, creating opportunities for staff to build new relationships and broaden and UHBW is already seeing an extra 70,000 patients a year through two community diagnostic centres in Cribbs Causeway and Weston-super-Mare and the long-term plan is for more patients to be seen and treated closer to home.
Telegraph
an hour ago
- Telegraph
NHS relaxes rules on weight-loss jabs for millions of diabetes patients
Millions more NHS patients could be offered Ozempic or Mounjaro in the biggest overhaul in diabetes treatment for a decade. The National Institute of Health and Care Excellence (Nice), the NHS medicines watchdog, has issued new draft guidance calling for the use of GLP-1 jabs, first developed for diabetes but now widely used for weight loss, to be ramped up significantly. It means the majority of people in Britain with type 2 diabetes – around five million in total – could be given the drugs to help prevent further illnesses. Experts hailed the proposed guidance as 'propelling treatment into the 21st century'. Prof Jonathan Benger, the deputy chief executive and chief medical officer at Nice, said the changes would mean 'more people will be offered medicines where it is right to do so'. He said: 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health.' He added that by recommending both classes of drug sooner, the NHS 'could help prevent heart attacks, strokes and other serious complications before they occur'. Drugs mimic hormones Under the draft guidance, doctors will be able to give the revolutionary drugs – GLP-1 receptor agonists – to diabetes patients who also have heart disease or are obese. They work by mimicking a hormone that regulates blood sugar and appetite. It has since also been revealed that they could help with a range of conditions such as cancer, heart disease and even dementia. Some 200,000 people are currently taking a GLP-1 injection on the NHS, three quarters of whom are using them for diabetes. The remainder are taking them for weight loss. It is thought as many as 1.3 million people in the UK are on the jabs privately. More than five million people in the UK are living with type 2 diabetes. It develops in adulthood and occurs when not enough of the hormone insulin is produced, leading to a rise in blood sugar levels. The new NHS guidance says the jabs should be considered in diabetes patients who have also been diagnosed with heart disease, heart failure, or have early onset type 2, which means they were diagnosed before age 40. People with both diabetes and obesity – a body mass index (BMI) over 35 – will also be able to get the jabs if they have not had success in bringing down their blood sugar levels within the first three months of using another drug. While there are no public figures on eligibility, millions of patients could fall into the relevant categories. It is common for people with diabetes to also suffer from heart issues and other related conditions, while up to 90 per cent are overweight or obese, with weight being the number one preventable cause of the condition. Diabetes UK estimates 168,000 people have early onset type 2, while the condition also causes about 250,000 heart attacks, strokes or cases of heart failure, each year – the leading cause of death in diabetes patients. Nice said the drugs were 'recommended as much for their cardiovascular benefits as for their glycaemic [blood sugar] benefits'. It estimates that 655,000 people with heart disease could benefit from the drugs, as well as 99,000 with early onset type 2. Nice said the initial rise in costs for the NHS would be offset in the longer term by reducing the need for other, sometimes more complex, treatment later on. It was revealed last week that the price of Mounjaro privately would be more than doubled from Sept 1 to a wholesale price of up to £300. The NHS bracing for an increase in demand and more people are expected to turn to competitor Wegovy. Some diabetes patients will already be eligible for, or taking, weight-loss jabs, on the NHS, but the draft guidance will mean more patients can access the drugs sooner without having to go to a specialist weight management service. To qualify for weight-loss drugs on the NHS, a person must currently have a BMI of over 40 and four related health conditions to receive Mounjaro, or attend a specialist weight management service, where waiting times can be up to a year or longer, with a BMI of over 35 and one related condition, to receive Wegovy. The draft guidance, which is out for consultation until October, also recommends making better use of another 'under-prescribed' class of drugs called SLGT-2 inhibitors. These daily pills include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. They reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. The new guidelines recommend patients who cannot tolerate metformin – the first choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. Drugs could protect heart and kidneys The watchdog said there was new evidence suggesting the drugs protect the heart and kidneys as well as controlling blood sugar, and could save almost 22,000 lives. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
